跳至主要内容
临床试验/2023-503686-26-02
2023-503686-26-02招募中2 期

PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis: The FIBRO-PET study.

St Antonius Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年9月20日最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
20
试验地点
1
主要终点
FAPI activity concentration in patients with predominant active fibrosis and predominant inflammation

研究概览

简要总结

To test the feasibility of differentiating predominant active fibrosis and predominant inflammation using PET imaging with FAPI in patients with PPF.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • ≥ 18 years of age
  • New diagnosis of PPF
  • A minimum of 20% of lung parenchyma is aberrant (fibrosis, inflammation or both)
  • MDT indication for treatment with either immunosuppressive drugs or antifibrotic drug

排除标准

  • Prior or current treatment with antifibrotic drugs
  • Active malignancy
  • Inability to undergo a PET/CT at the Sint Antonius Hospital
  • Incapacity to give informed consent personally

结局指标

主要结局

FAPI activity concentration in patients with predominant active fibrosis and predominant inflammation

FAPI activity concentration in patients with predominant active fibrosis and predominant inflammation

次要结局

  • Activity thresholds for positive FAPI-PET/CT confirming active fibrosis,
  • Correlation between baseline FAPI activity and ILD extent/degree of reticulation on HRCT as well as serum biomarkers for inflammation

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Andor van den Hoven

Scientific

St Antonius Hospital

研究点 (1)

Loading locations...

相似试验

PET/CT imaging with FAPI as a biomarker for the... | 临床试验